In the short term, gastric bypass surgery can profoundly improve glycemic control in adults with type 2 diabetes.
Gastric bypass surgery can improve glycemic control in adults with type 2 diabetes, but doesn’t cure diabetes, according to the largest community-based study of long-term diabetes outcomes after bariatric surgery, published online in Obesity Surgery.
The multisite study tracked 4,434 adults at Kaiser Permanente Northern California, Kaiser Permanente Southern California and HealthPartners for 14 years from 1995 to 2008. The research arms of all 3 of these integrated healthcare delivery systems-and Group Health Research Institute, where the study's results were analyzed-belong to the HMO Research Network. The patients had type 2 diabetes that was either controlled with medication or else uncontrolled, and they were also obese enough to be candidates for gastric bypass surgery.
“We found that for most of those people, diabetes either never remitted after gastric surgery or relapsed within five years,” says principal investigator David E. Arterburn, MD, MPH, a general internist and associate investigator at Group Health Research Institute.
The main impetus of the study is the growing numbers of Americans who are obese and have type 2 diabetes, according to Dr. Arterburn. Researchers have been disappointed with the results from attempts to treat diabetes with intensive lifestyle changes and intensive medical management, he says.
Prior research has shown that, in the short term, gastric bypass surgery can profoundly improve glycemic control in adults with type 2 diabetes-often even before they lose significant weight.
“That led some people to think that gastric bypass surgery might be a ‘cure’ for diabetes,” says Dr. Arterburn. “We wanted to see what happened in the longer term.”
It's still not clear whether diabetes relapse happens because of gaining weight back or because of the underlying progression of diabetes, but patients' weight before and after surgery was not strongly correlated with remission or relapse of diabetes in this population.
“Managed care and hospital decision-makers need to find the best ways to care for their many patients who are obese and have diabetes-ways that will serve those patients best in the long run,” says Dr. Arterburn. “Of course prevention is the best medicine, and gastric bypass surgery isn't for everyone, but for patients who are already obese and have diabetes, our results suggest that it's never too early to start considering the surgery.”
Go back to the Managed Healthcare Executive eNews newsletter.
Premiums for Employer-based Health Insurance Increased by 7% in 2024, Says KFF Report
Published: October 9th 2024 | Updated: October 9th 2024The 2024 increase is the same as last year's increase for family coverage. The foundation’s annual survey of employer health benefits also found that only 18% of large employers (200 employees are more) are covering the GLP-1 weight loss drugs.
Read More
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Doug Chaet of Value Evolutions Discusses Value-based Payment Models, Where They Stand and More
September 29th 2022In this episode of Tuning In to the C-Suite, Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing, the status of select payment models like bundled and episodic, and more.
Listen
Parity for Mental Health — Any Progress?
October 12th 2023Laws since 1996 have sought to assure that coverage of behavioral health treatments does not take a back seat to physical medicine. Amid a national crisis in mental illness and addiction, that new world of equality has not arrived. But is it on the way?
Read More